GoodRx(US:GDRX)2025-05-07 20:25Revenue Performance - First Quarter 2025 revenue increased by 3% to $203.0 million compared to $197.9 million in the same period last year[3] - Total revenue for Q1 2025 was $202.97 million, up 2.2% from $197.88 million in Q1 2024[30] - Revenue for Q1 2025 was $202,970,000, a 1.1% increase from $197,880,000 in Q1 2024[45] - For the full year 2025, the company anticipates revenue between $810 million and $840 million, representing a 2% to 6% growth compared to 2024[12] Segment Performance - Prescription transactions revenue rose by 2% to $148.9 million, driven by improved unit economics, despite a 4% decrease in Monthly Active Consumers[4] - Subscription revenue decreased by 7% to $21.0 million, primarily due to the discontinuation of the Kroger Savings Club partnership[5] - Pharma manufacturer solutions revenue increased by 17% to $28.6 million, reflecting organic growth and expanded market penetration[6] Profitability Metrics - Net income for the first quarter was $11.1 million, with a net income margin of 5.4%, compared to a net loss of $1.0 million in the prior year[6] - Net income for Q1 2025 was $11.05 million, a significant improvement from a net loss of $1.01 million in Q1 2024[30] - Adjusted Net Income for Q1 2025 was $34,363,000, compared to $32,586,000 in Q1 2024, showing a year-over-year increase of 5.4%[45] - Basic earnings per share for Q1 2025 was $0.03, compared to $(0.00) in Q1 2024, indicating a positive shift in profitability[45] Operational Efficiency - Adjusted EBITDA was $69.8 million, with an Adjusted EBITDA margin of 34.4%, up from 31.7% in the previous year[7] - Adjusted EBITDA for Q1 2025 reached $69,805,000, up from $62,787,000 in Q1 2024, indicating a growth of approximately 16%[42] - Adjusted EBITDA margin for Q1 2025 was 34.4%, up from 31.7% in Q1 2024, reflecting improved operational efficiency[42] - Operating income for Q1 2025 was $23.38 million, compared to $7.38 million in Q1 2024, an increase of 216.5%[30] - Operating income for Q1 2025 was $23,380,000, significantly higher than $7,381,000 in Q1 2024, indicating strong operational performance[49] Cash Flow and Assets - Cash flow from operating activities was $9.4 million, down from $42.6 million in the same quarter last year[8] - Cash and cash equivalents decreased to $300.98 million as of March 31, 2025, down from $448.35 million at the end of 2024, a reduction of 32.9%[27] - Total assets decreased to $1.30 billion in March 2025 from $1.39 billion in December 2024, a decline of 6.7%[27] - Total liabilities decreased to $640.92 million in March 2025 from $663.41 million in December 2024, a reduction of 3.4%[28] Consumer Metrics - The company exited the first quarter with over 7 million prescription-related consumers using GoodRx services[24] - Monthly Active Consumers decreased to 6.4 million in March 2025 from 6.6 million in December 2024, representing a decline of 3%[25] - Subscription plans decreased to 680,000 in March 2025 from 778,000 in March 2024, a decline of 12.6%[25] Cost Management - Total stock-based compensation expense for Q1 2025 was $19,174,000, down from $25,096,000 in Q1 2024, suggesting cost management efforts[45] - General and administrative expenses decreased to $29,630,000 in Q1 2025 from $41,108,000 in Q1 2024, representing a reduction of approximately 28%[47] Acquisition Costs - The company incurred $30 million in acquisition costs during Q1 2025[32] Future Guidance - Adjusted EBITDA guidance for 2025 is now between $273 million and $287 million, indicating a 5% to 10% growth compared to the previous year[12] - Adjusted EBITDA for Q1 2025 is expected to align with revenue, indicating stable operational performance moving forward[34]